Originally presented on: 12/16/2021
The first interchangeable biosimilar product was approved by the FDA in July 2021. These are widely used and have the potential to bring more affordability to patients. Insulin is one of these biosimilar products, and diabetes care and education specialists have an important role in being able explain this to their clients.
This webinar will help answer these questions:
-- What is a biosimilar?
-- What are the benefits of using an interchangeable biosimilar?
-- What does interchangeability mean and what is needed for the FDA to approve as interchangeable?
-- How is substitution at the pharmacy different from a person’s insurance plan switching their insulin due to formulary changes? (it’s not taking choice away, additional studies have been done that show…..use FDA language)
-- Is substitution available in all states?
-- Who is a good candidate for an interchangeable biosimilar?
-- What are key points to explain to your clients?
CE credit is not available for this activity.
Funding for this webinar is provided by Viatris.
This activity is designed for diabetes care and education specialists, including nurses, dietitians, pharmacists, nurse practitioners, clinical nurse specialists, physicians, physician assistants, and other healthcare providers interested in staying up to date on current practices of care for people with diabetes and other related conditions.
Katherine O’Neal, PharmD, MBA, BCACP, CDCES, BC-ADM, AE-C, CLS, FADCES
Associate Professor, College of Pharmacy
The University of Oklahoma Health Sciences Center
You will have access to this learning activity for a period of one year after you enroll, or whenever the activity expires (whichever comes first).
Expiration date: 12/16/2022